Simiso Sokhela to Pyridones
This is a "connection" page, showing publications Simiso Sokhela has written about Pyridones.
Connection Strength
1,297
-
DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
Score: 0,223
-
Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
Score: 0,217
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
Score: 0,214
-
Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
Score: 0,179
-
Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
Score: 0,055
-
Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
Score: 0,050
-
Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. J Antimicrob Chemother. 2022 10 28; 77(11):3110-3117.
Score: 0,049
-
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
Score: 0,046
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
Score: 0,046
-
Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
Score: 0,046
-
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
Score: 0,046
-
Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. Clin Infect Dis. 2021 08 16; 73(4):e1008-e1010.
Score: 0,045
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,042
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,039